冀衡医药
(002742)
| 流通市值：19.59亿 | | | 总市值：25.59亿 |
| 流通股本：5.24亿 | | | 总股本：6.84亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 240,714,752.19 | 141,899,006.39 | 899,848,459.7 | 737,265,157.37 |
| 营业收入 | 240,714,752.19 | 141,899,006.39 | 899,848,459.7 | 737,265,157.37 |
| 二、营业总成本 | 257,766,525.34 | 150,188,902.55 | 1,215,169,034.85 | 903,659,688.48 |
| 营业成本 | 211,588,823 | 123,779,542.51 | 758,751,662.02 | 599,141,521.28 |
| 税金及附加 | 3,259,148.8 | 1,516,080.49 | 16,275,769.7 | 9,279,486.98 |
| 销售费用 | 3,453,825.35 | 1,793,537.43 | 42,550,882.46 | 23,292,124.69 |
| 管理费用 | 25,806,071.52 | 15,878,658.36 | 168,447,541.26 | 125,183,578.92 |
| 研发费用 | 4,900,658.86 | 3,202,339.37 | 17,882,925.4 | 12,751,325.98 |
| 财务费用 | 8,757,997.81 | 4,018,744.39 | 211,260,254.01 | 134,011,650.63 |
| 其中:利息费用 | 7,897,872.1 | 4,025,428.45 | 201,441,635.87 | 122,305,481.39 |
| 其中:利息收入 | 69,826.1 | 34,363.39 | 34,936.6 | 75,200.72 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -1,266,626.06 | -1,284,680.22 | 48,662,256.37 | -30,146.05 |
| 资产处置收益 | -29,172.14 | -29,172.14 | -137,096.25 | 614,572.9 |
| 资产减值损失(新) | - | - | -158,704,633.03 | - |
| 信用减值损失(新) | -152,826.98 | 169,627.35 | 9,770,274.94 | -3,243,652.87 |
| 其他收益 | 2,508,596.3 | 1,375,110.88 | 4,924,847.13 | 3,441,988.37 |
| 四、营业利润 | -15,991,802.03 | -8,059,010.29 | -410,804,925.99 | -165,611,768.76 |
| 加:营业外收入 | 63,813.92 | 7,303.3 | 920,477.22 | 804,504.29 |
| 减:营业外支出 | 235,089.95 | 143,712.43 | 26,819,556.83 | 3,222,852.33 |
| 五、利润总额 | -16,163,078.06 | -8,195,419.42 | -436,704,005.6 | -168,030,116.8 |
| 减:所得税费用 | 4,560,462.16 | 510,059.99 | 22,084,948.87 | 10,977,694.08 |
| 六、净利润 | -20,723,540.22 | -8,705,479.41 | -458,788,954.47 | -179,007,810.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -20,723,510.22 | -8,705,479.41 | -405,393,354.93 | -179,007,810.88 |
| 终止经营净利润 | -30 | - | -53,395,599.54 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -20,138,456.92 | -8,073,276.27 | -419,682,691.5 | -177,748,131 |
| 少数股东损益 | -585,083.3 | -632,203.14 | -39,106,262.97 | -1,259,679.88 |
| 扣除非经常损益后的净利润 | -19,835,060.04 | -8,448,419.36 | -484,884,219.08 | -179,860,648.68 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.03 | -0.01 | -0.61 | -0.41 |
| (二)稀释每股收益 | -0.03 | -0.01 | -0.61 | -0.41 |
| 八、其他综合收益 | - | - | -19,517,324.15 | -18,083,892.6 |
| 归属于母公司股东的其他综合收益 | - | - | -19,517,324.15 | -18,083,892.6 |
| 九、综合收益总额 | -20,723,540.22 | -8,705,479.41 | -478,306,278.62 | -197,091,703.48 |
| 归属于母公司股东的综合收益总额 | -20,138,456.92 | -8,073,276.27 | -439,200,015.65 | -195,832,023.6 |
| 归属于少数股东的综合收益总额 | -585,083.3 | -632,203.14 | -39,106,262.97 | -1,259,679.88 |
| 公告日期 | 2026-08-15 | 2026-04-25 | 2026-03-31 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |